Welcome on BAPI website
Who are we?
History of BAPI
Bangladesh Association of Pharmaceutical Industries (BAPI) is the apex body representing the pharmaceutical companies of Bangladesh. Since its inception in 1972, BAPI has been playing a key role in developing the pharma sector in the country to promote access to affordable drugs. Closely working with the industry and regulatory authorities, the association promotes understanding of good manufacturing practices (GMP), and rightful implementation to ensure quality of the medicines.
Read moreRole of BAPI
- Since its inception in 1972, BAPI has been playing a key role in developing the pharma sector in the country to promote access to affordable drugs.
- Closely working with the industry and regulatory authorities, the association promotes understanding of good manufacturing practices (GMP), and rightful implementation to ensure quality of the medicines.
BAPI at a Glance
Today, Bangladesh has fulfilled another “National Aspiration” of “Turning an Import based Pharmaceutical Industry into an exporter of quality medicines”
Overview
Global Footprint
We are expanding our Global Footprint
Export is growing fast, the current export earning is more than $169.02 Mn (crossing the mark of BDT 14 Bn)
Bangladesh Government has declared Pharmaceuticals as the “Thrust Sector”
Approximately 1200 pharmaceutical products received registration for export over the last two years and are being exported to more than 150 countries including USA, UK, Canada, Australia, Germany, EU etc.
Prospect & opportunities
Competitive edge of Bangladesh Pharma
Global generics market is valued at around US $1.06 Tn and is projected to grow $1.30 Tn by 2020
Generic drugs will continue to grow maintaining healthy rate
Drugs worth more than $200 Bn coming off patent by 2025
Rising healthcare cost, particularly cost of medicine has become a global concern
API Park
Brief Outline
Plant Layout
- Total land area: 81 Hectares (200 acres)
- Overall project cost $30 million
- Plot handed over within 2018
- Local companies have already lined up with some US $300 million for investment for setting up facilities
